#1 Clinical Trials Search in Europe

METHYLPHENIDATE

Methylphenidate, commonly known by brand names such as Concerta, Ritalin, and Daytrana, is a central nervous system stimulant medication that has been extensively studied in clinical trials for various conditions. While most recognized for treating Attention Deficit Hyperactivity Disorder (ADHD), research has explored its potential benefits for other conditions like binge eating disorder, fatigue in cancer patients, cognitive impairment, and substance use disorders. This article examines how methylphenidate has been used in clinical trials, what these studies reveal about its effectiveness, and what patients might expect when participating in research involving this medication.

Table of Contents

What is Methylphenidate?

Methylphenidate is a central nervous system (CNS) stimulant medication primarily used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy. It works by inhibiting the reuptake of dopamine and norepinephrine, two neurotransmitters that play important roles in attention, focus, and executive function[1]. Methylphenidate is available under various brand names, including Ritalin, Concerta, Daytrana, Jornay PM, and Quillivant XR, among others.

Primary Uses of Methylphenidate

The primary FDA-approved use for methylphenidate is the treatment of ADHD in both children (age 6 and older) and adults[2]. It is also approved for the treatment of narcolepsy, a sleep disorder characterized by excessive daytime sleepiness and sudden attacks of sleep.

Beyond these approved uses, clinical trials have explored methylphenidate’s potential benefits for various other conditions, including:

  • Binge eating disorder[3]
  • Cognitive deficits associated with epilepsy[4]
  • Cancer-related fatigue[5]
  • Cognitive impairment in the elderly[6]
  • Treatment of ADHD in patients with substance use disorders[7]
  • Methamphetamine dependence[8]

Forms and Formulations

Methylphenidate is available in several formulations, each designed to provide different release patterns and durations of effect[9]:

  • Immediate-release (IR) tablets (e.g., Ritalin): Effects last approximately 3-4 hours, requiring multiple daily doses
  • Extended-release (ER) capsules/tablets (e.g., Ritalin LA, Concerta): Provide longer duration of action, typically 8-12 hours, allowing for once-daily dosing
  • Transdermal patch (Daytrana): Delivers medication through the skin, with effects lasting 9-12 hours depending on wear time
  • Oral suspension (Quillivant XR): Liquid formulation that provides extended release
  • Delayed-release formulation (Jornay PM): Taken in the evening with effects beginning the following morning and continuing throughout the day
  • Chewable tablets: Available for children who have difficulty swallowing pills

Each formulation has its own pharmacokinetic profile, with variations in how quickly the medication reaches peak blood levels (Tmax) and how long it remains active in the body[10].

Treatment of ADHD

Methylphenidate is considered a first-line treatment for ADHD. Clinical trials have consistently shown its effectiveness in reducing core ADHD symptoms of inattention, hyperactivity, and impulsivity[11].

In children with ADHD, methylphenidate treatment has demonstrated:

  • Improved attention span and ability to focus on tasks
  • Reduced hyperactive behaviors and impulsivity
  • Enhanced academic performance and productivity
  • Improved social interactions and behavior in school settings

For adults with ADHD, methylphenidate has shown benefits including:

  • Improved work performance and productivity
  • Better organization and time management
  • Reduced impulsive decision-making
  • Enhanced ability to maintain attention during conversations and meetings

Treatment response is typically assessed using standardized rating scales such as the ADHD Rating Scale (ADHD-RS), the Clinical Global Impression (CGI) scales, and the Conners’ Adult ADHD Rating Scales (CAARS)[12].

Effects on Cognition and Executive Function

Methylphenidate’s effects extend beyond core ADHD symptoms to influence various aspects of cognition and executive function[13]:

  • Working memory: Improved ability to hold and manipulate information temporarily
  • Processing speed: Enhanced rate at which the brain can process information
  • Response inhibition: Better ability to suppress inappropriate responses
  • Cognitive flexibility: Improved ability to switch between tasks or thought patterns
  • Sustained attention: Enhanced ability to maintain focus over extended periods
  • Response variability: More consistent performance on cognitive tasks

These cognitive benefits appear to be dose-dependent and may vary based on individual factors and the specific cognitive domains being assessed[14].

Treatment of Other Conditions

Binge Eating Disorder

Clinical trials have investigated methylphenidate as a potential treatment for binge eating disorder, with some promising results. In one randomized controlled trial, methylphenidate was compared to cognitive behavioral therapy for the treatment of binge eating disorder in overweight or obese adult females. The study assessed the effects on binge eating frequency, overall illness severity, and quality of life[3].

Cognitive Deficits in Epilepsy

Research has explored methylphenidate’s potential to improve attention and memory problems in people with epilepsy. A randomized, double-blind, placebo-controlled trial found that methylphenidate may improve attentional dysfunction in subjects with epilepsy without increasing seizure frequency[4].

Cancer-Related Fatigue

Methylphenidate has been studied as a treatment for cancer-related fatigue in patients with various types of cancer, including breast, gastrointestinal, lymphoma, myeloma, and lung cancer. A randomized, double-blind, placebo-controlled crossover trial evaluated whether methylphenidate could help control fatigue in patients undergoing chemotherapy or hormonal treatment[5].

Methamphetamine Dependence

Research has investigated whether methylphenidate could be effective in initiating and sustaining abstinence in methamphetamine-dependent individuals. A study compared methylphenidate to placebo in participants seeking treatment for methamphetamine dependence, with primary outcomes including the percentage of methamphetamine-negative urine samples and treatment retention[8].

Emergence from General Anesthesia

Some research has explored methylphenidate’s potential to decrease emergence time from isoflurane general anesthesia. A randomized, double-blind, placebo-controlled trial assessed whether methylphenidate affects the time from termination of isoflurane to extubation[15].

Side Effects and Safety Considerations

As with any medication, methylphenidate can cause side effects. Common adverse effects include[16]:

  • Decreased appetite and weight loss
  • Sleep difficulties (insomnia)
  • Headaches
  • Stomach aches
  • Increased heart rate and blood pressure
  • Irritability or mood changes
  • Nervousness or anxiety

Less common but more serious side effects may include:

  • Cardiovascular effects (significant increases in blood pressure or heart rate)
  • Growth suppression in children (typically minor and often temporary)
  • Psychiatric adverse effects (such as psychosis or mania, particularly in susceptible individuals)
  • Seizures (rare, especially in patients without a history of seizures)
  • Priapism (prolonged and painful erection) in rare cases

When used as prescribed, methylphenidate has a well-established safety profile. However, due to its stimulant properties and potential for misuse, it is classified as a Schedule II controlled substance in the United States[17].

Use in Special Populations

Children and Adolescents

Methylphenidate is approved for use in children age 6 and older. Special considerations for this population include monitoring for effects on growth (height and weight), appetite, and sleep patterns. Some research has explored its use in younger children (ages 4-5), but with careful attention to dosing and side effect monitoring[18].

Adults with ADHD

Adults with ADHD may require different dosing strategies than children. Extended-release formulations are often preferred for adults to provide all-day symptom control with once-daily dosing. Clinical trials have established the efficacy of methylphenidate in adult ADHD patients[19].

Individuals with Comorbid Conditions

Research has examined methylphenidate’s use in people with ADHD plus additional conditions:

  • ADHD and Autism Spectrum Disorder: Studies suggest methylphenidate can help manage ADHD symptoms in children with autism, though they may be more sensitive to side effects and might benefit from lower starting doses[20].
  • ADHD and Substance Use Disorders: Research has explored methylphenidate treatment in methadone-maintained patients with ADHD, with attention to both efficacy and potential for misuse[7].
  • ADHD and Down Syndrome: Clinical trials have investigated the safety and efficacy of methylphenidate in children with both Down syndrome and ADHD, who have a 3-5 times greater prevalence of ADHD than typically developing children[21].

Dosing Considerations

Methylphenidate dosing is highly individualized based on several factors[22]:

  • Age and weight: Children typically start at lower doses than adults, often with weight-based calculations
  • Formulation: Different release mechanisms require different dosing schedules
  • Individual response: Some people may respond to lower doses while others require higher doses for optimal effect
  • Tolerability: Side effects may limit the maximum tolerable dose

Dosing strategies commonly include:

  • Starting with a low dose and gradually titrating upward
  • Monitoring response and side effects at each dose level
  • Finding the “optimal dose” that provides maximum benefit with minimal side effects
  • Considering timing of doses relative to daily activities and sleep schedule

For example, with extended-release formulations like Concerta, typical adult dosing might start at 18 or 36 mg once daily, potentially increasing to 72 mg daily based on response. The delayed-release formulation Jornay PM is unique in that it’s taken in the evening (typically between 6:30 and 9:30 PM), with effects beginning the following morning[23].

In summary, methylphenidate is a well-established medication with demonstrated efficacy for ADHD and emerging evidence for several other conditions. Its various formulations provide flexibility in addressing individual patient needs, while careful attention to dosing and potential side effects helps optimize its therapeutic benefits.

Aspect Details
Common Formulations – Immediate-release tablets (Ritalin)
– Extended-release capsules/tablets (Concerta, Ritalin LA)
– Transdermal patches (Daytrana)
– Liquid suspensions (Quillivant XR)
– Evening-dosed formulations (Jornay PM)
Conditions Studied – ADHD in children, adolescents, and adults
– ADHD in special populations (Down syndrome, autism)
– Binge eating disorder
– Fatigue in cancer patients
– Cognitive deficits in epilepsy
– Substance use disorders
– Mild cognitive impairment
– Emergence from anesthesia
Commonly Measured Outcomes – ADHD symptom reduction
– Executive function improvement
– Cognitive performance
– Task attentiveness
– Quality of life
– Sleep quality
– Duration of drug effect
– Pharmacokinetic parameters
Safety Monitoring – Blood pressure and heart rate
– Sleep patterns
– Appetite changes
– Skin reactions (for patches)
– Tics and movement disorders
– Mood changes
– Seizure frequency (in epilepsy patients)
Common Trial Designs – Randomized controlled trials
– Crossover studies
– Dose-escalation trials
– Open-label extensions
– Pharmacokinetic comparison studies
– Placebo-controlled trials
Dosage Ranges Studied – Children: 10-72 mg daily (weight-adjusted)
– Adults: 18-100 mg daily
– Typically titrated upward to find optimal dose
– Higher doses for extended-release formulations

FAQ

  • What conditions is methylphenidate being studied for in clinical trials? While methylphenidate is best known for treating ADHD in children and adults, clinical trials have investigated its use for multiple conditions. These include binge eating disorder, fatigue in cancer and sarcoidosis patients, methamphetamine dependence, cognitive deficits in epilepsy patients, post-anesthesia emergence, cognitive improvement in mild cognitive impairment, and ADHD symptoms in patients with Down syndrome or autism. Researchers are interested in its effects on attention, behavior regulation, and cognitive function across different populations.
  • How is methylphenidate administered in clinical trials? Clinical trials have tested various formulations and administration methods. These include immediate-release tablets (like Ritalin), extended-release capsules and tablets (like Concerta, Ritalin LA, and Jornay PM), transdermal patches (Daytrana), and liquid oral suspensions (Quillivant XR). Trials often compare different delivery systems to understand how they affect the onset, duration, and consistency of the medication's effects. The dosing schedule varies by formulation – some require multiple daily doses while extended-release versions are taken once daily, and newer formulations like Jornay PM are taken in the evening to provide effects upon waking the next morning.
  • What side effects have been monitored in methylphenidate clinical trials? Clinical trials carefully monitor various side effects including changes in heart rate, blood pressure, sleep quality, appetite, and the occurrence of tics. For transdermal patch formulations like Daytrana, researchers specifically evaluate skin reactions. Some studies examine potential cardiac effects through ECG monitoring. Trials also assess potential psychiatric effects like changes in mood and anxiety. For participants with specific conditions, such as epilepsy, researchers monitor whether methylphenidate affects seizure frequency. The safety profile is particularly important when studying the medication in new populations or for off-label uses.
  • How do researchers measure if methylphenidate is working in clinical trials? Researchers use various assessment tools to measure methylphenidate's effectiveness. For ADHD trials, standardized rating scales like the ADHD Rating Scale, Conners' Continuous Performance Test, Clinical Global Impression scales, and the IOWA Conners scale measure changes in attention, hyperactivity, and impulsivity. For cognitive function, tests like digit span, Stroop tests, and specialized memory assessments are used. Quality of life questionnaires help understand the medication's impact on daily functioning. Some studies also use objective measurements like electroencephalography (EEG) or magnetic resonance imaging (MRI) to observe changes in brain activity or structure.
  • What happens to participants after a methylphenidate clinical trial ends? After a trial concludes, follow-up procedures vary by study design. Some trials include extension phases where participants can continue receiving the medication to gather long-term safety and efficacy data. In other studies, participants return to their regular treatment regimen. If the medication showed benefit, participants might be given information about continuing the treatment through their healthcare provider. Trials typically include final assessments to document the participant's condition when leaving the study. Some studies also include post-treatment follow-up visits to assess any lasting effects or to monitor for any delayed side effects after discontinuation.

Ongoing Clinical Trials on METHYLPHENIDATE

  • Study on Methylphenidate for Reducing Fatigue in Childhood Brain Tumor Survivors

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

Glossary

  • ADHD (Attention Deficit Hyperactivity Disorder): A neurodevelopmental disorder characterized by persistent patterns of inattention, hyperactivity, and impulsivity that interferes with functioning or development.
  • AISRS (Adult ADHD Investigator Symptom Rating Scale): A clinical assessment tool used to measure the severity of ADHD symptoms in adults, consisting of 18 items directly adapted from diagnostic criteria.
  • AUC (Area Under the Curve): A pharmacokinetic measurement that represents the total drug exposure over time. It helps researchers understand how much of the drug reaches the bloodstream.
  • Bioequivalence: The relationship between two pharmaceutical products containing the same active ingredient when they produce similar blood concentrations over a similar time period.
  • CGI (Clinical Global Impression): A clinician-rated assessment tool that measures illness severity (CGI-S) and improvement or change (CGI-I) in patients with mental disorders.
  • Cmax: The maximum concentration of a drug in the blood, cerebrospinal fluid, or target organ after administration, used to determine the absorption rate of drugs.
  • Crossover Study: A clinical trial design where participants receive different treatments in a specific sequence over time, allowing each participant to serve as their own control.
  • Double-blind: A study design where neither the participants nor the researchers know which treatment is being administered, reducing the risk of bias.
  • ER/Extended-Release: A drug formulation designed to release the active ingredient over an extended period, reducing the frequency of dosing.
  • Executive Function: A set of cognitive processes including working memory, flexible thinking, and self-control that are necessary for planning, focusing attention, and multitasking.
  • MPH: Abbreviation for methylphenidate hydrochloride, the active ingredient in medications like Ritalin and Concerta.
  • OROS (Osmotic Release Oral System): A drug delivery technology used in some extended-release formulations like Concerta that uses osmotic pressure to deliver the drug at a controlled rate.
  • Pharmacokinetics: The study of how drugs move through the body, including absorption, distribution, metabolism, and excretion.
  • Placebo: An inactive substance designed to look like the drug being tested, used as a control in clinical trials to determine the true effect of the treatment.
  • QOLIE (Quality of Life in Epilepsy): A standardized questionnaire that assesses health-related quality of life in patients with epilepsy, covering areas like emotional well-being, cognitive functioning, and social support.
  • Randomized Controlled Trial (RCT): A study where participants are randomly assigned to receive either the experimental treatment or a control (placebo or standard treatment), considered the gold standard for clinical research.
  • SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham) Rating Scale: An assessment tool used to evaluate classroom behavior and attention in children with ADHD.
  • Tmax: The time after administration when a drug reaches its maximum concentration in the blood, important for understanding how quickly a medication takes effect.
  • Transdermal System: A drug delivery method where medication is absorbed through the skin (like the Daytrana patch), allowing for continuous delivery of the active substance.
  • Washout Period: A time period during a clinical trial when participants stop taking any study medications or previous treatments, allowing the body to clear these substances before starting a new treatment phase.

References

  1. https://clinicaltrials.gov/study/NCT00302393
  2. https://clinicaltrials.gov/study/NCT01259492
  3. https://clinicaltrials.gov/study/NCT01921582
  4. https://clinicaltrials.gov/study/NCT04419272
  5. https://clinicaltrials.gov/study/NCT00516269
  6. https://clinicaltrials.gov/study/NCT02326038
  7. https://clinicaltrials.gov/study/NCT00061087
  8. https://clinicaltrials.gov/study/NCT01044238
  9. https://clinicaltrials.gov/study/NCT00989950
  10. https://clinicaltrials.gov/study/NCT01118702
  11. https://clinicaltrials.gov/study/NCT00269776
  12. https://clinicaltrials.gov/study/NCT04507204
  13. https://clinicaltrials.gov/study/NCT01238822
  14. https://clinicaltrials.gov/study/NCT00815841
  15. https://clinicaltrials.gov/study/NCT02327195
  16. https://clinicaltrials.gov/study/NCT00434213
  17. https://clinicaltrials.gov/study/NCT00780208
  18. https://clinicaltrials.gov/study/NCT03546400
  19. https://clinicaltrials.gov/study/NCT01338818
  20. https://clinicaltrials.gov/study/NCT02255565
  21. https://clinicaltrials.gov/study/NCT04219280
  22. https://clinicaltrials.gov/study/NCT02730572
  23. https://clinicaltrials.gov/study/NCT06577779